Editing Coronary artery disease (section)

====Anti-platelet therapy====
[[Clopidogrel]] plus aspirin (dual anti-platelet therapy) reduces cardiovascular events more than aspirin alone in those with a [[STEMI]]. In others at high risk but not having an acute event, the evidence is weak.<ref>{{cite journal | vauthors = Squizzato A, Bellesini M, Takeda A, Middeldorp S, Donadini MP | title = Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular events | journal = The Cochrane Database of Systematic Reviews | volume = 2017 | pages = CD005158 | date = December 2017 | issue = 12 | pmid = 29240976 | pmc = 6486024 | doi = 10.1002/14651858.CD005158.pub4 }}</ref> Specifically, its use does not change the risk of death in this group.<ref>{{cite web|title=FDA Drug Safety Communication: FDA review finds long-term treatment with blood-thinning medicine Plavix (clopidogrel) does not change risk of death|url=https://www.fda.gov/Drugs/DrugSafety/ucm471286.htm|website=FDA|access-date=25 January 2016|date=6 November 2015|url-status=live|archive-url=https://web.archive.org/web/20160204011823/https://www.fda.gov/Drugs/DrugSafety/ucm471286.htm|archive-date=4 February 2016}}</ref> In those who have had a stent, more than 12 months of clopidogrel plus aspirin does not affect the risk of death.<ref>{{cite journal | vauthors = Elmariah S, Mauri L, Doros G, Galper BZ, O'Neill KE, Steg PG, Kereiakes DJ, Yeh RW | display-authors = 6 | title = Extended duration dual antiplatelet therapy and mortality: a systematic review and meta-analysis | journal = Lancet | volume = 385 | issue = 9970 | pages = 792–98 | date = February 2015 | pmid = 25467565 | pmc = 4386690 | doi = 10.1016/S0140-6736(14)62052-3 }}<!--|access-date=26 October 2015--></ref>